However, urgentlyneeded cut-off levels of AMH in patients withendocrinological risk factors, such as PCOS andthe hormonally induced overreaction of the ovarianresponse as in OHSS, are still missing to supportthe clinical decision (11, 25-28). The gene discussed is AMH; the disease is polycystic ovary syndrome.